Keio Hospital to start physician-led trial of Cyfuse's bioprinted knee implant
Cyfuse Biomedical said Keio University Hospital will run a physician-initiated trial of its bioprinted KCF-BC1 knee implant, with the release citing rabbit and minipig data and the earnings effect for the year to December 2026 still under review.